Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.
2.

Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients.

MacConell L, Gurney K, Malloy J, Zhou M, Kolterman O.

Diabetes Metab Syndr Obes. 2015 May 18;8:241-53. doi: 10.2147/DMSO.S77290. eCollection 2015.

3.

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.

Ridge T, Moretto T, MacConell L, Pencek R, Han J, Schulteis C, Porter L.

Diabetes Obes Metab. 2012 Dec;14(12):1097-103. doi: 10.1111/j.1463-1326.2012.01639.x. Epub 2012 Jul 19.

4.

Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.

Grimm M, Han J, Weaver C, Griffin P, Schulteis CT, Dong H, Malloy J.

Postgrad Med. 2013 May;125(3):47-57. doi: 10.3810/pgm.2013.05.2660.

PMID:
23748506
5.

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes.

Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L.

Cardiovasc Diabetol. 2011 Mar 16;10:22. doi: 10.1186/1475-2840-10-22.

6.

Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies.

Lehrke M, Marx N, Patel S, Seck T, Crowe S, Cheng K, von Eynatten M, Johansen OE.

Clin Ther. 2014 Aug 1;36(8):1130-46. doi: 10.1016/j.clinthera.2014.06.008. Epub 2014 Jul 8. Erratum in: Clin Ther. 2014 Nov 1;36(11):1705.

7.
8.

Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).

Rosenstock J, Raccah D, Korányi L, Maffei L, Boka G, Miossec P, Gerich JE.

Diabetes Care. 2013 Oct;36(10):2945-51. doi: 10.2337/dc12-2709. Epub 2013 May 22.

9.

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. doi: 10.1016/j.clinthera.2008.08.006. Erratum in: Clin Ther. 2008 Oct;30(10):1937.

PMID:
18803987
10.

Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.

Feagan BG, Macdonald JK.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD000543. doi: 10.1002/14651858.CD000543.pub3. Review. Update in: Cochrane Database Syst Rev. 2016;4:CD000543.

PMID:
23076889
11.

Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index.

Pencek R, Blickensderfer A, Li Y, Brunell SC, Anderson PW.

Postgrad Med. 2012 Jul;124(4):21-32. doi: 10.3810/pgm.2012.07.2567.

PMID:
22913891
12.

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis.

Williams-Herman D, Round E, Swern AS, Musser B, Davies MJ, Stein PP, Kaufman KD, Amatruda JM.

BMC Endocr Disord. 2008 Oct 27;8:14. doi: 10.1186/1472-6823-8-14.

13.

Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.

Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, Hoogwerf BJ, Rosenstock J.

Ann Intern Med. 2011 Jan 18;154(2):103-12. doi: 10.7326/0003-4819-154-2-201101180-00300. Epub 2010 Dec 6.

PMID:
21138825
14.

Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.

Wang Y, Parker CE, Bhanji T, Feagan BG, MacDonald JK.

Cochrane Database Syst Rev. 2016 Apr 21;4:CD000543. doi: 10.1002/14651858.CD000543.pub4. Review.

PMID:
27101467
15.

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, Trautmann M, Porter L.

J Clin Endocrinol Metab. 2011 May;96(5):1301-10. doi: 10.1210/jc.2010-2081. Epub 2011 Feb 9.

PMID:
21307137
16.

Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.

Norwood P, Liutkus JF, Haber H, Pintilei E, Boardman MK, Trautmann ME.

Clin Ther. 2012 Oct;34(10):2082-90. doi: 10.1016/j.clinthera.2012.09.007. Epub 2012 Sep 29.

PMID:
23031623
17.

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes.

Williams-Herman D, Engel SS, Round E, Johnson J, Golm GT, Guo H, Musser BJ, Davies MJ, Kaufman KD, Goldstein BJ.

BMC Endocr Disord. 2010 Apr 22;10:7. doi: 10.1186/1472-6823-10-7.

18.

Safety and efficacy of twice-daily exenatide in Taiwanese patients with inadequately controlled type 2 diabetes mellitus.

Lu CH, Wu TJ, Shih KC, Ni E, Reed V, Yu M, Sheu WH, Chuang LM.

J Formos Med Assoc. 2013 Mar;112(3):144-50. doi: 10.1016/j.jfma.2012.02.027. Epub 2012 Jun 12.

19.

Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥ 65 years) with type 2 diabetes.

Iqbal N, Allen E, Öhman P.

Clin Interv Aging. 2014 Sep 4;9:1479-87. doi: 10.2147/CIA.S68193. eCollection 2014.

20.

Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).

Wysham C, Blevins T, Arakaki R, Colon G, Garcia P, Atisso C, Kuhstoss D, Lakshmanan M.

Diabetes Care. 2014 Aug;37(8):2159-67. doi: 10.2337/dc13-2760. Epub 2014 May 30. Erratum in: Diabetes Care. 2014 Oct;37(10):2895. Diabetes Care. 2015 Jul;38(7):1393-4.

PMID:
24879836

Supplemental Content

Support Center